错配修复基因在乙型肝炎病毒相关肝细胞癌中表达的影响因素

doi:10.20047/j.issn1673-7210.2022.31.07

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influencing factors of mismatch repair gene(MMR) expression in hepatitis B virus (HBV)-associated hepatocellular carcinoma. Methods The MMR immunohistochemical results of 125 patients with HBV-associated hepatocellular carcinoma admitted to Beijing Youan Hospital, Capital Medical University from December 2019 to June 2021 were retrospectively analyzed. The patients were divided into deficiency MMR (dMMR) group (18 cases) and proficiency MMR (pMMR) group (107 cases). The influencing factors of dMMR in patients with HBV-associated hepatocellular carcinoma were further analyzed. Results The deletion of dMMR group included the loss of MutL homologue 1 (MLH1)/postmeiotic protein isolate 2 (PMS2) expression (4 cases), the loss of MLH1 expression (1 case), the loss of MutS protein homologue 2 (MSH2) /PMS2 expression (1 case), and the loss of PMS2 expression (12 cases). The necrosis rate, microvascular invasion rate, glutamic-oxaloacetic transaminase level, and abnormal prothrombin level in dMMR group were lower than those in pMMR group, and the differences were statistically significant (P ＜ 0.05). There were significant differences in differentiation degree, Edmondson grade, and P53 protein intensity between the two groups (P ＜ 0.05). The results of multivariate analysis showed that Edmondson grade and glutamic-oxaloacetic transaminase level were independent influencing factors of dMMR (P ＜ 0.05). Conclusion dMMR is a low-frequency event in HBV-associated hepatocellular carcinoma, which is related to Edmondson grade and glutamic-oxaloacetic transaminase level, and may be an effective target for the treatment of the disease.

Key words： Hepatocellular carcinoma Mismatch repair gene Hepatitis B virus Gene deficiency

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Yuxue NING Qiqi CAI Yuying GUAN Yuanyue YANG Pengxiang CHEN Dexi

Cite this article:

GAO Yuxue NING Qiqi CAI Yuying GUAN Yuanyue YANG Pengxiang CHEN Dexi. Influencing factors of mismatch repair gene expression in hepatitis B virus-associated hepatocellular carcinoma[J]. 中国医药导报, 2022, 19(31): 31-34,48.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.31.07 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I31/31

[1] Gao YX，Yang TW，Yin JM，et al. Progress and prospects of biomarkers in primary liver cancer（Review）[J]. Int J Oncol，2020，57（1）：54-66.
[2] Gao Y，Xu Q，Li X，et al. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma [J]. Cell Death Dis，2022，13（3）：213.
[3] Ekiba K，Otsuka M，Funato K，et al. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA [J]. J Hepatol，2022， 76（1）：53-62.
[4] Yang H，Bae SH，Nam H，et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance [J]. J Hepatol，2022，77（3）：632-641.
[5] Sandmann L，Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed [J]. Hepatology，2022， 75（5）：1075-1077.
[6] Papatheodoridi M，Tampaki M，Lok AS，et al. Risk of HBV reactivation during therapies for HCC：A systematic review [J]. Hepatology，2022，75（5）：1257-1274.
[7] Péneau C，Imbeaud S，La Bella T，et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma [J]. Gut，2022，71（3）：616-626.
[8] Ratovomanana T，Cohen R，Svrcek M，et al. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair [J]. Gastroenterology，2021，161（3）：814- 826.
[9] Yao J，Zhen Y，Fan J，et al. Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population [J]. Cancer Biol Med，2022，19（5）：707-732.
[10] Einarsson H，Runarsdottir JR，Tryggvason T，et al. Universal tumor screening in a population with MSH6- and PMS2-associated Lynch syndrome [J]. Genet Med，2022， 24（5）：999-1007.
[11] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）[J].中国实用外科杂志，2020，29（18）：3224-3228.
[12] Chalasani NP，Ramasubramanian TS，Bhattacharya A，et al. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma [J]. Clin Gastroenterol Hepatol，2021，19（12）：2597-2605.
[13] Zhou ZX，Lujan SA，Burkholder AB，et al. How asymmetric DNA replication achieves symmetrical fidelity [J]. Nat Struct Mol Biol，2021，28（12）：1020-1028.
[14] Alim I，Loke J，Yam S，et al. Cancer Risk C（CR-C），a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency [J]. Genet Med，2022， 24（9）：1821-1830.
[15] Crisafulli G，Sartore-Bianchi A，Lazzari L，et al. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients [J]. Cancer Discov，2022，12（7）：1656-1675.
[16] Fang H，Zhu X，Yang H，et al. Deficiency of replication-independent DNA mismatch repair drives a 5-methylcytosine deamination mutational signature in cancer [J]. Sci Adv，2021，7（45）：eabg4398.
[17] Liu YL，Cadoo KA，Maio A，et al. Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome [J]. Genet Med，2022，24（6）：1187- 1195.
[18] Hinrichsen I，Kemp M，Peveling-Oberhag J，et al. Promoter methylation of MLH1，PMS2，MSH2 and p16 is a phenomenon of advanced-stage HCCs [J]. PLoS One，2014，9（1）：e84453.
[19] Helal TE，Khamis NS，El-Sharkawy TM，et al. Immunohistochemical expression of mismatch repair genes（hMSH2 and hMLH1）in hepatocellular carcinoma in Egypt [J]. APMIS，2010，118（12）：934-940.
[20] Li J，Li N，Azhar MS，et al. Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma [J]. Sci Rep，2022，12（1）：12330.
[21] Zhu X，Wang Z，Qiu X，et al. Rs2303428 of MSH2 Is Associated with Hepatocellular Carcinoma Prognosis in a Chinese Population [J]. DNA Cell Biol，2018，37（7）：634- 641.
[22] Wang L，Bani-Hani A，Montoya DP，et al. hMLH1 and hMSH2 expression in human hepatocellular carcinoma [J]. Int J Oncol，2001，19（3）：567-570.
[23] 张翠娟，李晓明，丘礼武，等.DNA错配修复基因甲基化在肝细胞癌发生发展中的作用[J].中华病理学杂志，2004， 33（5）：36-39.
[24] Zekri AR，Sabry GM，Bahnassy AA，et al. Mismatch repair genes（hMLH1，hPMS1，hPMS2，GTBP/hMSH6，hMSH2）in the pathogenesis of hepatocellular carcinoma [J]. World J Gastroenterol，2005，11（20）：3020-3026.
[25] Karahan B，Argon A，Y?覦ld?覦r?覦m M，et al. Relationship between MLH-1，MSH-2，PMS-2，MSH-6 expression and clinicopathological features in colorectal cancer [J]. Int J Clin Exp Pathol，2015，8（4）：4044-4053.